Company: ARTL
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001640334-25-001429
Chunk: 427

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 427
---
 and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our Common Stock would likely decline. We have organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.

Risk Factor Summary

Risks Related to our Business and Product Candidates:

 ·We will need to raise additional financing to support our business objectives. We cannot be sure we will be able to obtain additional financing on terms favorable to us when needed, or at all. If we are unable to obtain additional financing to meet our needs, our operations may be adversely affected or terminated.    ·We are currently receiving Research and Development, or R&D, tax credits from the UK in connection with our clinical trials being conducted in the UK. With effect for accounting periods starting on or after April 1, 2024, expenditure on certain staffing costs in connection with activities which take place outside the UK as part of our clinical trials, will not qualify for R&D tax credits unless restrictive conditions are met.    ·If we fail to comply with our obligations under our patent licenses with third parties, we could lose license rights that are vital to our business.    ·Changes in regulatory requirements or other unforeseen circumstances may impact the timing of the initiation or completion of our clinical trials.    ·We face many of the risks and difficulties frequently encountered by relatively new companies with respect to our operations.    ·We have no mature product candidates and may not be successful in licensing any.    ·Even if we are successful in licensing lead product candidates, resource limitations may limit our ability to successfully develop them. 

Risk Factors Related to our DAT Strategy:

 ·SOL is a highly volatile asset, and fluctuations in the price of SOL may influence our financial results and the market price of our listed securities.    ·SOL and other digital assets are novel assets and are subject to significant legal and regulatory uncertainty.    ·Our SOL digital asset holdings may not be recognized as cash or financial assets under Nasdaq listing standards, which could jeopardize our continued listing and adversely affect the liquidity and market price of our Common Stock.    ·Our Solana treasury strategy could divert resources and attention away from